



272 1651

|   |                                     |                             |  |                                 |                          |
|---|-------------------------------------|-----------------------------|--|---------------------------------|--------------------------|
| <b>AMENDMENT TRANSMITTAL LETTER (Large Entity)</b>  |                                     |                             |  | <b>Docket No.</b><br>112701-593 |                          |
| Applicant(s): K. Bortlik et al.   |                                     |                             |  |                                 |                          |
| Application No.<br>10/057,660   | Filing Date<br>01/25/02             | Examiner<br>R.A. David      | Customer No.<br>29157  | Group Art Unit<br>1651          | Confirmation No.<br>4348 |
| Invention: <b>PRIMARY COMPOSITION COMPRISING A LIPOPHILIC BIOACTIVE COMPOUND</b>  |                                     |                             |  |                                 |                          |
| <b>COMMISSIONER FOR PATENTS:</b>  |                                     |                             |  |                                 |                          |
| Transmitted herewith is an amendment in the above-identified application.   |                                     |                             |  |                                 |                          |
| The fee has been calculated and is transmitted as shown below.  |                                     |                             |  |                                 |                          |
| <b>CLAIMS AS AMENDED</b>  |                                     |                             |  |                                 |                          |
|   | CLAIMS REMAINING<br>AFTER AMENDMENT | HIGHEST #<br>PREV. PAID FOR | NUMBER EXTRA<br>CLAIMS PRESENT   | RATE                            | ADDITIONAL<br>FEE        |
| TOTAL CLAIMS  | 28 -                                | 28 =                        | 0  | x \$50.00                       | \$0.00                   |
| INDEP. CLAIMS   | 2 -                                 | 3 =                         | 0  | x \$200.00                      | \$0.00                   |
| Multiple Dependent Claims (check if applicable) <input type="checkbox"/>  |                                     |                             |  |                                 | \$0.00                   |
| <b>TOTAL ADDITIONAL FEE FOR THIS AMENDMENT</b>  |                                     |                             |  |                                 | <b>\$0.00</b>            |
| <input checked="" type="checkbox"/> No additional fee is required for amendment.<br><input type="checkbox"/> Please charge Deposit Account No. _____ in the amount of _____<br><input type="checkbox"/> A check in the amount of _____ to cover the filing fee is enclosed.<br><input checked="" type="checkbox"/> The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account 02-1818<br><input checked="" type="checkbox"/> Any additional filing fees required under 37 C.F.R. 1.16.<br><input checked="" type="checkbox"/> Any patent application processing fees under 37 CFR 1.17.<br><input type="checkbox"/> Payment by credit card. Form PTO-2038. |                                     |                             |  |                                 |                          |
| <b>WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.</b>   |                                     |                             |  |                                 |                          |
| _____<br>Signature  |                                     |                             | Dated: June 13, 2005   |                                 |                          |
| Robert M. Barrett (Reg. No. 30,142)<br>Bell, Boyd & Lloyd LLC<br>P.O. Box 1135<br>Chicago, Illinois 60690-1135<br>Tel: 312/807-4204<br>Fax: 312/827-8185  |                                     |                             | <div style="border: 1px solid black; padding: 5px;"><p>I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on</p><p>06/13/05<br/>(Date)</p><p style="text-align:center"><br/>Signature of Person Mailing Correspondence<br/>Heather Foster</p><p style="text-align:center">Typed or Printed Name of Person Mailing Correspondence</p></div> |                                 |                          |
| cc:   |                                     |                             |  |                                 |                          |
|   |                                     |                             |  |                                 |                          |
|   |                                     |                             |  |                                 |                          |

Appl. No. 10/057,660

Reply to Office Action of March 22, 2005



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s): K. Bortlik et al.

Appl. No.: 10/057,660

Conf. No.: 4348

Filed: January 25, 2002

Title: PRIMARY COMPOSITION COMPRISING A LIPOPHILIC BIOACTIVE  
COMPOUND

Art Unit: 1651

Examiner: R.A. David

Docket No.: 112701-593

Mail Stop Amendment

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

**AMENDMENT**

Sir:

In response to the non-final Office Action dated March 22, 2005, please amend the above-identified patent application as follows:

**Amendments to the Claims** are reflected in the listing of claims which begins on page 2 of this paper.

**Remarks** begin on page 6 of this paper.